Novo Nordisk Completes P-Ib/IIa Study of Subcutaneous Amycretin in Overweight or Obese People
Shots:
- The P-Ib/IIa trial assessed amycretin (Q1W) vs PBO in overweight or obese patients (n=125) in 5 parts
- Part A (single ascending dose) assessed PK & determined the initial dose for Part B (multiple dose arm), which evaluated safety/tolerability over 36wks. Parts C, D, & E (PoC) evaluated weight loss with 3 doses (1.25mg, 5mg, & 20mg) over 12wks. each
- Data showed Amycretin-treated patients achieved a weight loss of 9.7% (1.25mg, 20 wks.), 16.2% (5mg, 28wks.), & 22.0% (20 mg, 36wks.) from a 92.7kg (baseline), while PBO-treated patients gained weight (~1.9%, 2.3% & 2.0%). Results demonstrated weight lowering potential based on which Novo to plan further clinical development
Ref: Globenewswire | Image: Novo Nordisk
Related News:- Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
